drug · small molecule
orelabrutinib
Phase 3updated 3mo agoby $ZBIO Zenas BioPharma, Inc.🔗 ChEMBL
Phase 3community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and 18 investigational indications.
targets
Tyrosine-protein kinase BTK
all catalysts(0)
nothing on the calendar yet
Trials studying orelabrutinib
- phase3A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- phase3A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- phase2Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
- phase3A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
- phase3A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- phase2Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
- phase3ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- phase3Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that